Screening for Chronic Obstructive Pulmonary Disease
医学
肺病
内科学
重症监护医学
作者
Carol M. Mangione,Michael J. Barry,Wanda K. Nicholson,Michael D. Cabana,Aaron B. Caughey,David Chelmow,Tumaini R. Coker,Esa M. Davis,Katrina E Donahue,Carlos Roberto Jaén,Martha Kubik,Li Li,Gbenga Ogedegbe,Lori Pbert,John Ruiz,James Stevermer,Chien‐Wen Tseng,John B. Wong
出处
期刊:JAMA [American Medical Association] 日期:2022-05-10卷期号:327 (18): 1806-1806被引量:60
Chronic obstructive pulmonary disease (COPD) is an irreversible reduction of airflow in the lungs. Progression to severe disease can prevent participation in normal activities because of deterioration of lung function. In 2020 it was estimated that approximately 6% of US adults had been diagnosed with COPD. Chronic lower respiratory disease, composed mainly of COPD, is the sixth leading cause of death in the US.
Objective
To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a reaffirmation evidence update that focused on targeted key questions for benefits and harms of screening for COPD in asymptomatic adults and treatment in screen-detected or screen-relevant adults.
Population
Asymptomatic adults who do not recognize or report respiratory symptoms.
Evidence Assessment
Using a reaffirmation process, the USPSTF concludes with moderate certainty that screening for COPD in asymptomatic adults has no net benefit.
Recommendation
The USPSTF recommends against screening for COPD in asymptomatic adults. (D recommendation)